This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Elafibranor for previously treated primary biliary cholangitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Elafibranor

  • is an agonist of the peroxisome proliferator-activated receptors (PPAR) alpha (α), delta (δ), and gamma (γ), intracellular receptors with major effects on bile acid synthesis and transport as well as lipid metabolism and glucose homeostasis (1):
    • studies of other PPAR agonists such as pioglitazone and fenofibrate have suggested at least partial improvement in disease activity with their use in several liver diseases
      • the PPARα agonist bezafibrate has been shown to improve liver tests and histology in patients with primary biliary cholangitis
      • elafibranor has been shown to improve serum enzymes in several diseases including nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (1)

NICE states (2):

  • Elafibranor is recommended, within its marketing authorisation, as an option for treating primary biliary cholangitis in adults, when used:
    • with ursodeoxycholic acid (UDCA), if the primary biliary cholangitis has not responded well enough to UDCA, or
    • alone, if UDCA cannot be tolerated

Reference:

  1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Elafibranor. [Updated 2024 Jul 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK605979/
  2. NICE (November 2024). Elafibranor for previously treated primary biliary cholangitis

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.